Browsing by Subject "Rhabdomyolysis"
Now showing items 1-3 of 3
-
Gender-specific Rhabdomyolysis risk in Alzheimer’s disease patients receiving memantine: a pharmacovigilance study
(Brac University, 2023-10)Alzheimer’s disease is a neurodegenerative disease. Using FDA Adverse Event Reporting System database, a pharmacovigilance study for gender specific rhabdomyolysis risk in memantine users was conducted between January ... -
A pharmacovigilance study on Donepezil: signal detection of rhabdomyolysis and death
(Brac University, 2023-02)Alzheimer’s disease is an age-related neurodegenerative disease that effects the cognitive ability of a person. The cholinesterase inhibitor “donepezil” is used to treat Alzheimer's disease. Donepezil has shown the greatest ... -
Signal detection of rhabdomyolysis and death for rivastigmine: a pharmacovigilance study
(Brac University, 2023-02)The following study utilized the Food and Drug Administration Adverse Event Reporting System (FAERS) database to determine the AChI inhibitor, rivastigmine’s effect on patient mortality as well as its side effect of ...